tryptophan — amyotrophic lateral sclerosis
Computational selective-reversal hypothesis (moderate selectivity); supplement lane.
Research intelligence — a ranked, filtered hypothesis, not a validated cure. No disease or efficacy claim. Computational transcriptomic prediction, pending wet-lab.
WHITESPACE · 0 trials · supplement
Same mechanism or overlapping tags. Computational, pending wet-lab.
⚠ Trial-status classification + computational prediction — not an efficacy grade. Pending wet-lab.
tryptophan as a NAD+ precursor / survival hypothesis for amyotrophic lateral sclerosis — WHITESPACE in the clinical-trial registry.
Classify tryptophan for amyotrophic lateral sclerosis: whitespace, graveyard, or active? Justify, then state one limit.
Objective: registry triage + computational != efficacy
How a BD package is built: measured-selectivity → tox gate → trial-whitespace → IP/regulatory triage (the method, shown for teaching).
Gated for paid: full ranked candidate lists + licensable novel-composition leads (paid / NDA)
Unlock the full dossier on the Exchange.
The full dossier — ranked candidate lists, measured-selectivity detail, published-literature corroboration, and known-compound structures — is delivered as a PDF to your checkout email. The teaser and the free academic package above are always public.
Buy this dossier →Provenance: Prepackaged on Hetzner from the full-registry trial index + Foundry engine attributes. Computational, pending wet-lab. · Updated 2026-06-03.
Research intelligence, not medical, efficacy, or freedom-to-operate advice. All candidate signals are computational transcriptomic predictions pending wet-lab validation. The subscriber owns development and claims decisions and is responsible for its own freedom-to-operate. CONFIDENTIAL — MightyCloud Collective / OmniRayn Foundry.